Enterprise Value
-9.119M
Cash
40.15M
Avg Qtr Burn
-11.69M
Short % of Float
3.29%
Insider Ownership
7.67%
Institutional Own.
1.43%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OTIPRIO (ciprofloxacin otic suspension) 6% Details Bilateral Otitis Media and AOE (Acute Otitis Externa) | Approved Quarterly sales | |
OTO-413 Details Tinnitus, Ear illness/ disorder, Hearing loss | Phase 2a Update | |
OTIVIDEX® Details Ménière's disease | Failed Discontinued | |
OTO-313 Details Tinnitus, Ear illness/ disorder | Failed Discontinued |